The Latest News from the Medical Device Industry's Top Suppliers |
Cyberkinetics' Braingate Technology Wins Prestigious "R&D 100" Award
Annual Competition Recognizes 100 Most Technologically Significant New Products of the Year
FOXBOROUGH, MA – July 17, 2007 — Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: CYKN; Cyberkinetics) announced that the Company's BrainGate Neural Interface System was named an "R&D 100" award winner by R&D Magazine, ranking it as one of the most innovative new products of the year. The R&D 100 awards honor excellence and innovation and are presented each year to 100 new products. The BrainGate System, a brain-computer interface technology, is designed to control movement of assistive devices by neural signaling – that is, by thought alone. The technology is currently being investigated in two clinical trials in people with severe paralysis due to spinal cord injury, stroke and ALS (Lou Gehrig's disease). "We are honored to be picked for this prestigious industry award," stated Timothy R. Surgenor, President and Chief Executive Officer of Cyberkinetics Neurotechnology Systems, Inc. “It reflects the achievements of our work in neural signaling technology and its potential to significantly improve the quality of life for people with severe paralysis." "We are developing the BrainGate System to one day enable paralyzed people to achieve more independence by using their own thoughts to control a wide range of external devices, including wheelchairs, as well as to someday move their own limbs," added John P. Donoghue, Ph.D., Cyberkinetics' Chief Scientific Officer and Director of the Brain Science Program at Brown University. Battelle, the world's largest non-profit independent research and development organization, is co-winner of the award with Cyberkinetics. "In 2006 we made a breakthrough in the development of new techniques that more accurately interpreted the brain signals we were gathering," said Chad Bouton, Senior Research Engineer at Battelle Medical Device Solutions, who worked with the BrainGate engineering team. "For the first time this allowed a person with the sensor to demonstrate control of a wheelchair directly through thought alone." Winning candidates of the R&D 100 awards are identified by an independent panel of judges. This year's awards will be presented to winners in Chicago on October 18, 2007. The annual competition was first introduced in 1963. Previous winners have included the automated teller machine (1973), the Nicoderm anti-smoking patch (1992), and high definition television (1998). About the BrainGate System About Battelle About Cyberkinetics Neurotechnology Systems, Inc. Forward-Looking Statements This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress. Such statements may be considered "forward-looking" within the meaning of the United States Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of words like "may," "will," "could," "should," "project," "believe," "anticipate," "expect," "plan," "estimate," "forecast," "potential," "intend," "continue" and variations of these words or comparable words. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Forward-looking statements include, but are not limited to, statements concerning our future expectations, plans, prospects and future operating results as well as projections of cash and marketable securities and sufficiency of funding for capital expenditures. Actual results may differ materially from those indicated by these forward-looking statements as a result of various factors including risks related to: our ability to secure regulatory approval for our products; our access to additional capital; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales and distribution of our products; our development of products; our ability to obtain and maintain patent protection for our discoveries and products; and our limited operating history; as well as those risks more fully discussed in the "Risk Factors" section of the Company's Registration Statement on Form SB-2 (file no. 333-144333) and our other public documents filed with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Cyberkinetics Contact: Berry & Company Public Relations Contact: Battelle Contact: | ||
published date: 10-05-2007 |
